CooperCompanies strategic pivot to eye care, shares backed by Stifel
27.06.2026 - 09:31:11 | ad-hoc-news.de
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 09:30.
CooperCompanies (US21664P1039) is drawing analyst attention on NASDAQ as it advances plans to sell its CooperSurgical business. Stifel recently reiterated a Buy rating with an $85 price target after management reported progress in divestiture talks and outlined a more focused contact lens strategy. Stifel's update via Yahoo Finance
What Stifel is pricing in
On June 12, Stifel reaffirmed its positive view on CooperCompanies, keeping a Buy rating while setting the price target for the shares at $85. The call followed company commentary that discussions to sell CooperSurgical have moved forward and that several interested parties are engaged. Analyst note summary
Stifel's modeling assumes that once CooperSurgical is divested, CooperCompanies will operate essentially as a pure-play contact lens manufacturer. In that scenario, the brokerage estimates the stock's fundamental value around $80 a share, implying roughly a 21 percent upside versus the level used in its analysis. Valuation commentary
How the strategy is shifting
CooperCompanies historically combined two pillars: CooperVision in soft contact lenses and CooperSurgical in women's health products and fertility solutions. Management has now disclosed that legal issues impacting CooperSurgical have been resolved, clearing the way for a potential sale to one of several interested buyers. Legal resolution detail
A divestiture would leave CooperCompanies much more concentrated in the vision care market, where CooperVision already competes with peers such as Johnson & Johnson’s eye-care unit and Alcon. Analysts see a more streamlined portfolio as a potential driver for clearer margins and capital allocation, even if it reduces diversification across healthcare segments. Sector peer comparison
Background and price data on CooperCompanies
All recent articles, disclosures and market data on the CooperCompanies shares are available in the dedicated topic area and through the company’s investor relations site.
What the company sells today
CooperCompanies generates most of its revenue through CooperVision, a global supplier of soft contact lenses for daily wear, extended wear and specialty applications such as toric lenses for astigmatism. Product lines include silicone hydrogel lenses and myopia management offerings aimed at slowing the progression of nearsightedness in younger patients. Company product overview
Where the stock trades today
The CooperCompanies shares (US21664P1039) trade on NASDAQ under the ticker COO; as of the latest available close on June 26, 2026, they were quoted around 71 US dollars, in line with recent data from specialist platforms that track the stock’s after-hours level at 71.02 dollars. Recent price reference
CooperCompanies at a glance
- Company: The Cooper Companies, Inc.
- ISIN: US21664P1039
- WKN: 859289
- Ticker: COO
- Trading venue: NASDAQ
- Price (as of 2026-06-26, 16:00): 71.02 USD
- Market cap: approximately 7.0 billion USD (as of late June 2026, based on recent price data and shares outstanding)
- Sector / industry: Health Care / Medical Devices
- Index membership: S&P 500
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any transaction. All data are based on sources believed to be reliable but may be subject to revision; investors should conduct their own research or consult a licensed financial advisor before making investment decisions.
